New Horizons: Peptides, GLP-1s, and the FDA Big Shift

Peptides in Orthopaedics: What the 2026 AAOS Review Reveals

The American Academy of Orthopaedic Surgeons just published a comprehensive review on BPC-157, TB-500, and GHK-Cu. Here's what the evidence actually shows about peptides for injury recovery.

BLMP6: The Peptide That Hunts Down Metastatic Breast Cancer Cells

UTHealth Houston researchers engineered a peptide that targets fibulin-4 on metastatic breast cancer cells, dramatically suppressing tumors in mice. Here's how it works and why it matters.

CJC-1295/Ipamorelin and Sleep Problems: Why It Happens and How to Fix It

Started CJC-1295/Ipamorelin and now you can't sleep? You're not alone. Here's why GH secretagogues disrupt sleep and what actually works to fix it.

News

FDA Removes 12 Peptides from Restricted List — Compounding Access Could Return by July 2026

The FDA has removed 12 peptides from its restricted Category 2 list and scheduled PCAC meetings for July 2026. BPC-157, TB-500, KPV, and 9 others could become legally available for compounding again.

News

FDA Removes 12 Peptides from Category 2 Restricted List

The FDA removed 12 peptides including BPC-157, TB-500, and MOTs-C from its restricted Category 2 list on April 15, 2026. Here is what changed, what it means, and what happens next.

The GLP-1 Pill Wars Have Begun. Here's What Actually Changed.

Eli Lilly's Foundayo just became the first GLP-1 pill you can take without food restrictions. Novo Nordisk's oral semaglutide is heading to teenagers. The injection era is ending — but the details matter.

News

The FDA Is Reviewing 12 Peptides. Here's What That Actually Means.

After two years of restrictions, the FDA is provisionally removing 12 peptides from its banned list and scheduling formal reviews. Which ones are back, what the science says, and what patients should know right now.

Compound Spotlight

The Peptide That Heals Everything: What 150 Studies Actually Reveal

BPC-157 was isolated from human gastric juice in the 1990s. Three decades later, 150+ papers suggest it might be the most versatile repair peptide ever studied — and almost nobody's heard of it.

The Drug Quietly Revolutionizing 6 Areas of Medicine (And It's Not About Weight)

Everyone knows Ozempic for weight loss. But semaglutide is being studied for Alzheimer's, heart disease, liver failure, addiction, and chronic inflammation — and the data is extraordinary.

Protocol Update

How to Build a Peptide Stack That Actually Makes Scientific Sense

Forget the forum hype. Here's a systematic framework for designing peptide protocols — from objective definition to compound selection, synergy principles, and the mistakes that trip up 90% of beginners.

Why Smart Researchers Stack Peptides: The Science of Synergy

BPC-157 + TB-500. Ipamorelin + CJC-1295. Semax + Selank. The most effective peptide protocols aren't single compounds — they're carefully designed combinations. Here's the science behind why.

This week brought a rare alignment in the world of metabolic and regenerative medicine: regulatory clarity, clinical progress, and a reminder that the most interesting work happens in the details, not the headlines. The FDA removed 12 peptides from its Category 2 restricted list, effectively ending a two-year bottleneck that had limited research and clinical access. These are not experimental unknowns - they are compounds with hundreds of published studies and established safety profiles. BPC-157, TB-500, GHK-Cu, and others have moved closer to legitimate compounding availability, with formal advisory committee meetings scheduled for July. What changed is not the science; it is the willingness to acknowledge it. At the same time, the GLP-1 landscape shifted again. Eli Lilly Foundayo became the first GLP-1 pill without food restrictions, and Novo Nordisk cleared a path toward adolescent use of oral semaglutide. The injection era is not ending, but the convenience threshold has moved. These drugs are being studied now for Alzheimer's, heart disease, addiction, liver failure, and chronic inflammation - applications that dwarf their original weight loss indication. What connects these stories is a shift from prohibition to investigation. The tools we talked about in theory are becoming available in practice. That does not mean they are simple, or safe, or appropriate for everyone. It means the questions we ask next will be different. Instead of can we access these? we get to ask how do we use them well?.

Peptides in Orthopaedics: What the 2026 AAOS Review Reveals

The AAOS review examined BPC-157, TB-500, GHK-Cu, and several growth-hormone secretagogues through the lens of orthopedic recovery. What stands out is not just the positive findings - it is that these compounds have been studied in controlled settings for decades without major safety signals. The review suggests peptides may have legitimate adjunctive roles in soft tissue recovery, tendon healing, and post-surgical rehabilitation, particularly where inflammation control and angiogenesis matter. The caveat: quality varies enormously, and clinical protocols remain largely empirical. But the field has moved from should we study this? to how do we study this properly?

BLMP6: The Peptide That Hunts Down Metastatic Breast Cancer Cells

Metastatic breast cancer treatment has long relied on systemic chemotherapy with broad toxicity. UTHealth researchers engineered BLMP6, a peptide that selectively binds fibulin-4 - a protein highly expressed on metastatic breast cancer cells but minimally present in healthy tissue. In mouse models, the peptide delivered cytotoxic payloads directly to tumors, suppressing growth while sparing normal organs. The approach hints at a broader strategy: using peptides as targeting vectors rather than standalone drugs. It is early work, but it demonstrates that precision delivery might solve the toxicity problem that has limited peptide therapeutics in oncology.

CJC-1295/Ipamorelin and Sleep Problems: Why It Happens and How to Fix It

GH secretagogues increase growth hormone, but they also increase cortisol and can shift circadian timing. The sleep disruption that follows CJC-1295/Ipamorelin use is not random - it reflects the relationship between growth hormone pulses, cortisol awakening response, and deep sleep architecture. The fix is not stopping; it is timing. Shifting injections earlier in the day, reducing dose frequency, and addressing cortisol through adaptogenic support often restores sleep without sacrificing benefits. The key insight: sleep disruption signals hypothalamic-pituitary-adrenal axis stress, not just individual drug effects.

FDA Removes 12 Peptides from Restricted List — Compounding Access Could Return by July 2026

Category 2 was a bottleneck. Peptides on the list required special approval for compounding, effectively limiting access. The April removal does not mean unregulated availability - compounding still requires prescriptions and quality standards - but it shifts peptides from restricted to review pending. July's PCAC meetings will determine permanent status. For now, compounding pharmacies can include these peptides without special FDA permission, provided they meet sterility and potency standards. The practical effect: wider availability, more data collection, and clearer safety signals.

FDA Removes 12 Peptides from Category 2 Restricted List

The GLP-1 Pill Wars Have Begun. Here's What Actually Changed.

Foundayo's formulation removes the requirement for fasting before dosing - a small change with major implications. Oral semaglutide already absorbed poorly without specific conditions. The bigger story is adolescent approval pathways. When Novo Nordisk's oral semaglutide reaches teens, it will normalize GLP-1 use for developing bodies - with unknown effects on growth, puberty, and long-term metabolic programming. Adults trade convenience for GI side effects; children trade developmental flexibility. The convenience threshold has moved, but the cost-benefit calculation has not.

The FDA Is Reviewing 12 Peptides. Here's What That Actually Means.

The Peptide That Heals Everything: What 150 Studies Actually Reveal

Isolated from human gastric juice in 1993, BPC-157 is stable orally, crosses membranes, and appears to accelerate healing in tendon, ligament, muscle, and nervous tissue. The mechanisms - angiogenesis modulation, nitric oxide pathway interaction, and gut-brain axis effects - are plausible. What is missing is large-scale human data, though smaller studies and decades of compounding use suggest minimal toxicity. The compound's stability outside refrigeration makes it unusual among peptides. Whether it lives up to the heals everything reputation depends on outcome measures, but the mechanistic rationale is stronger than for many approved drugs.

The Drug Quietly Revolutionizing 6 Areas of Medicine (And It's Not About Weight)

Everyone knows Ozempic for weight loss. But semaglutide is being studied for Alzheimer's, heart disease, liver failure, addiction, and chronic inflammation — and the data is extraordinary. The implications extend beyond the immediate findings.

How to Build a Peptide Stack That Actually Makes Scientific Sense

Most protocols fail from polypharmacy - adding compounds without removing redundancies or addressing interactions. A systematic approach starts with the primary objective, identifies rate-limiting pathways, then selects compounds with complementary mechanisms. BPC-157 and TB-500 both support angiogenesis but through different pathways; combining them may provide temporal coverage. Ipamorelin and CJC-1295 share downstream effects but differ in pulse characteristics. Synergy requires understanding which pathways amplify versus compete. Most importantly: single compounds fail when underlying foundations are ignored.

Why Smart Researchers Stack Peptides: The Science of Synergy

BPC-157 increases angiogenesis and collagen synthesis; TB-500 promotes cell migration and reduces inflammation. Together, they cover creation and organization of new tissue. Ipamorelin provides acute GH pulses without cortisol elevation; CJC-1295 maintains elevated baseline GH. Semax and Selank share structural similarity and anxiolytic effects but Semax is better studied for cognitive enhancement. The principle: temporal coverage, pathway complementarity, and dose optimization. Stacking is not about more drugs; it is about better coverage of biological time and mechanism.